Candida parapsilosis expresses and secretes two aspartic proteinases  by Fusek, Martin et al.
Volume 327, number 1, 108-l 12 FEBS 12741 
:D 1993 Federation of European Blochemlcal Socletles 00145793/93/$6.00 
July 1993 
~~~~~d~ ~ r~~~~~~~~s expresses and secretes two aspartic proteinases 
Martin Fusek”, Elizabeth A. Smith”, Michel Monodb and Stephen I. Foundling” 
“Laborutor? of Protein Crystaflograph~: Protein Stlrdies Program, Oklahoma Medrccrf Reseurch Forcndatiorr. Okluhomu City, OK 
73104, USA and ‘Luburato~re de Mycafogie, Serwce de Der~~~~tofogie, Cenfre ~~~~itul~er ~~ili~er~~tuire ~~~~d~iis~ 1011~ull.~at~~e, 
Switzerland 
Received 17 May 1993 
We have Isolated and characterized a second aspartic proteinase secreted by the CHUV E-18 strain of Currt.Qda pcrrcrps~losts. This proteinase IS 
produced at a level correspondmg to approaimately 25% of the productlon of the mam protemase described earlier [l]. This minor protemase has 
similar molecular weight and pH optimum but differs m the lsoelectrlc point and m the specificity when compared with the major secreted form. 
The determmation of the ammo terminal amino acid sequence ldentlfied this mmor form of Citnriidti p~r~zp.~z~o.\/.~ aspartlc proteinase as a protein 
winch corresponds to the sequence deduced from genomlc DNA orlgmally reported as a pseudogene [l]. We conclude that strzun CHUV E-18 of 
Cu&idrr pmzps~/o.su expresses and secretes two different aspartlc proteinases. 
Aspartic proteinase: Proteinase mhibltor; Pseudogene, C’trt~iircirr parqsik)si.c 
1. INTRODUCTION 
Infections caused by Candida opportunistic yeasts are 
becoming one of the major threats for immune compro- 
mised patients [2], such as those infected with human 
immunodeficiency virus, cancer patients, transplant re- 
cipients and patients with other immunodeficiencies. 
The conversion of the otherwise nonvirulent and mildly 
pathogenic ~a~d~da microorganism to an invasive one 
is being connected to several secreted virulence factors 
[3,4]. Among these factors are the extracellular aspartic 
proteinases. These enzymes are considered to be the 
contributing part of the mechanism by which Cartdida 
penetrates the host’s mucosal membranes [5]. Several of 
the extracellular aspartic proteinases were isolated and 
partially characterized from the yeasts ~a~~d~da Africans 
161, Candida tropicalis and Candida parupsilosis [7,8]. 
The amino acid sequences of these aspartic proteinases 
were deduced from the corresponding genomic DNA 
sequences [ 1,9, IO]. 
Based upon the invasive role that Cun~i~du aspartic 
proteinases are suggested to play in the development of 
severe systemic Candida infection and disseminated 
candidamycoses (recently summarized by Riichel et al. 
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Abhrevicitions. SDS, sodium dodecyl sulfate; BSA, bovme serum albu- 
min; CPAP, C~~z~z~u ~r~~.~~~~.~r~ aspartic proteinase 
[5]), these proteinases offer a new target for the synthetic 
inhibitor design. 
A wealth of information exists for the inhibition of 
several other aspartic proteinases which has been 
gained during the design of inhibitors for human renin 
[l 11. and for the retroviral proteinases of the AIDS virus 
[12]. These studies show that substrate specificity in the 
aspartic proteinase family is complex and composite. 
Chemical specificity is essentially the sum of the numer- 
ous interactions of amino acid side chains, peptide 
backbone atoms and substrate atoms in combination, 
interacting in total in the active site cleft of the enzyme. 
Even minor differences in the primary and hence the 
tertiary structures of these enzymes can lead to mark- 
edly different substrate specificities. 
It was shown recently that there is a difference in 
primary structures of the secreted aspartic proteinases 
from different strains of Candidu albicans yeast [5]. 
These differences in primary structure affect both the 
chemical properties and specificity of these enzymes [5]. 
When examining the sequences of the genomic DNA 
from Cundida parapsilosis coding for aspartic pro- 
teinases, Veragh et al. [1] have detected two different 
DNA sequences coding for putative extracellular aspar- 
tic proteinases. One of the genes was identified by 
amino terminal sequencing of the extracellular protein 
as the secreted aspartic proteinase. but the second gene, 
since its product was not detected, was considered an 
untranslated gene or pseudogene. 
In this paper we report new data which shows that the 
product of the second aspartic proteinase gene is found 
in Candida parapsilosis cultures grown in liquid media 
with BSA as the sole source of nitrogen. This proteinase 
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is secreted and has very similar molecular weight but 
different isoelectric point and catalytic properties com- 
pared to the major secreted enzyme. 
2. EXPERIMENTAL 
2.1. Ye0~r culture 
Cmdida parapsihis CHUV E- 18 is mamtained and replated every 
6 to 8 weeks on Sabouraud agar plates (Difco). For growmg Candldu 
yeast m hquid culture the following procedure IS used. 50 ml of stertle 
1 2% YCB medium (Difco) contaming 0.2% of bovine serum albumin 
(BSA) (Sigma, USA) is adjusted to pH 4.0 and maculated with several 
colonies of Candida yeast from agar plates. This culture is grown 
overnight at 30°C in an orbital incubator shaker (200 rpm). The next 
morning 0.5 ml of this overnight culture IS used for the inoculation of 
500 ml of the same culture media. After 4 days of growth at 30°C. the 
500 ml cultures are centrifuged (30 min at 7,000 x g) and the superna- 
tant is sterile filtered to remove any infectious cellular material. This 
sterile supernatant is used for enzyme tsolatton. 
20 ml of SP-Trisacryl resin (IBF. France) is added to the stenle 
filtered supernatant for batch absorption of the enzyme (the resin is 
pre-equtlibrated in 15 mM sodium citrate, pH 4 0). Before the addition 
of the ion exchange resin the pH of the supernatant is adjusted to pH 
4 0. The resin IS removed after 30 min of stirring at room temperature, 
washed thoroughly with 15 mM citrate buffer pH 4.0 and then the 
protemase is eluted from the resin using 300 mM curate buffer pH 4.0. 
Efuted protems are then dialyzed against the washing buffer overnight 
and applied to a Mono-S cation exchange FPLC column (5 x 5. Phar- 
macia, Sweden). This step provides the final purtficatmn step and 
elution from the column is effected usmg a linear gradtent of NaCl as 
shown on Fig. 1. The yield of the two proteins defined here as CPAP#l 
and CPAP#2 are 4 and 1 mg/l of culture, respectively (CPAP. Candida 
pffr~ps~~osjs Asparttc Proteinuse). 
2.3. Sz)S eIrctrop~lore~~1.~. rsoelectrie focusing md Western blottmg 
The SDS polyacrylamide electrophoresis is carried out using a 4% 
stacking gel pH 6.8 and 15% separating gel pH 8.8 with 0.1% of SDS 
in all buffers. Samples were reduced wtth /3-mercaptoethenol before 
application on the gel. Isoelectric focusmg IS carrted out usmg a Phar- 
macta Phast System (Pharmacta, Sweden) using precast Pharmacia 
IEF gels (pi 3-9). Western blotting IS performed on a semi-dry elec- 
troblotter (Enprotech, USA) using the standard procedures recom- 
mended by the manufacturer. Antibodtes used for western blotting 
were as described by Togni et al. [lo]. 
2.4. Actlnty determination 
The proteolytic activity in chromatographed fracttons is determined 
usmg two photometric methods. For fast screenmg of activity in eluted 
fractions we use a solution of 1% bovine hemoglobin (Sigma, USA) 
dissolved m 100 mM sodium curate buffer, pH 3.4 Ahquots (5 ~1) of 
the eluted fractions are incubated with 1 ml of the hemoglobin solution 
at 37°C for 30 min. The reaction is stopped by the addition of 200 ~1 
of 10% trichloracetic acid. Any precipitate is removed by centrifuga- 
tion and the absorbance of the supernatant IS read at 280 nm. This 
photometric absorbance assay is linear in the range of 0.01 to 1 .O AU. 
One unit of specific activity is defined as the change in absorbance at 
A ZHOnm of I AU by 1 mg ofproteinase in incubatton time of T = 30 min. 
The kmettc measurements were made usmg a spectrophotometric 
synthetic peptide substrate Lys-Pro-Ala-Glu-Phe-Phe@-NO?)-Ala- 
Leu. where Phe@-NO,) is the punr-mtrophenylalanyl group. The 
cleavage of the bond between the Phe and Phe(p-NOJ residues ytelds 
a decrease in absorbance at 310 nm. Measurements of initial rates of 
thts change are measured to give initial veloctty 1131. Measurements 
are done m 100 mM sodmm citrate pH 3.5 monitoring the change in 
absorbance at 310 nm using a Vartan DMS model 6000 spectro- 
photometer (Varian, Austria). 
2.5. Ammo ternurzal srquencmg 
Ammo terminal sequencing was done on an ABI gas sequencer 
usmg the procedures and chemicals recommended by the manufac- 
turer. 
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Fig. 1. A chromatogmm of the tsolation of two aspartic proteinases from the supernatant of liquid culture of Candidu ~~r~~~i~o~r~ yeast. The column 
used was a Pharmacia Mono S (5 x S), equilibrated m 15 mM citrate pH 4.0 buffer. Flow rate was set at 1 mlmin-‘. The NaCl elutton gradient 
developed is shown in the diagram. The solid line plot shows the absorbance profile for the eluted CPAP#I and CPAP#2 and the dashed line overlaid 
shows the correlated proteolytic activity for the two proteinases. 
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Fig. 2. Analysis of the molecular weights of the purified Candida 
parupsilosis aspartic proteinases by Coomassie blue (R250) stained 
15% SDS-PAGE gel. Both CPAP#l (lane A) and CPAP#2 run with 
at similar positions and with estimated molecular weights in the range 
of 35 kDa to 38 kDa. 
3. RESULTS AND DISCUSSION 
During the isolation of CPAP using the Mono S col- 
umn, we observed a second distinct peak which eluted 
later in the NaCI gradient {Fig. 1). This second minor 
peak had proteolytic activity at pH 3.4 and it was la- 
belled as CPAP#2. The protein was first compared with 
the CPAP#l by SDS electrophoresis (Fig. 2) then by 
western blot analysis using antibodies raised against 
CPAP#I [14] (data not shown) and finally by isoelectro- 
focusing gel electrophoresis (data not shown). The elec- 
-Al 
123456 7 2 3 4 5 6 
trophoretic mobility was the same for both proteins and 
CPAP#2 crossreacted with antibodies to CPAP#I. The 
isoelectric point for CPAP#l was found to be 5.3 and 
4.4 for CPAP#2. This difference in isoelectric point 
explains the difference in the retention on the Mono S 
column of CPAP#2. These data are in good agreement 
with the data by Riichel [14] who observed a minor 
impurity with the p1 6.5. 
When comparing the activity of two proteinases using 
macromolecular substrates (hemoglobin and BSA) we 
found that the specific activity of the minor peak is 
similar (Fig. 3 and Table I) and the products of the 
cleavage of BSA gave a similar pattern for both en- 
zymes {Fig. 3). Both enzymes had an apparent pH opti- 
mum close to pH 3.5 (Fig. 2) and both were inhibited 
by pepstatin A. 
A large difference was observed between CPAP#l 
and CPAP#2 when the rates of cleavage of the synthetic 
spectrophotometric substrate were measured. The dif- 
ference in initial rates of catalytic activity was more than 
2 orders of magnitude between CPAP#l and CPAP#2. 
CPAP#2 has a lower activity towards this synthetic 
substrate (Table I). This indicates that the two pro- 
teinase species CPAP#l and CPAP#2 have a different 
chemical structure, particularly in the region of the sub- 
strate binding site which is responsible for substrate 
recognition and specificity of binding. 
In order to determine the molecular differences be- 
tween the two proteins we determined the amino termi- 
nal amino acid sequences. As seen in Fig. 4, the se- 
quence of CPAP#l corresponds to the reported amino 
terminus of the genomic gene sequence for the major 
aspartic proteinase. The second peak CPAP#2, is iden- 
tified as the protein derived from the putative untrans- 
lated genomic gene sequence, or pseudogene. 
The authors in the original paper [l] have demon- 
strated that there are two different gene sequences pres- 
ent in the strain CHUV E-18 of Candida ~a~a~s~losis, 
l----B7 
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Fig. 3. pH profile of cleavage of BSA by the two aspartic proteinase from Ca~djda puyapsilosis. Panel A, CPAP#I; pane1 B. CPAP#2. Lane 1, 
pH 2.5; lane 2. pH 3.0; lane 3, pH 3.5; lane 4, pH 4.0; lane 5, pH 4.5: and lane 6. pH 5.0. 
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1 . 10 . 20 . 30 . 40 . 50 
CPAP#l MVAIVTLTRQVLLTIALALFAQGAAIPEEAAXRDDNPGFVALDFDVLRXP 
** 
CPAP#Z MTTIAIFTKNVLLAIAFALFAQGAAIPD-PAXRDDNPGFVALDFEVTRXP 
July 1993 
60 . 70 . 80 . 90 . 100 
CPAPfl LNLTEALLREXRDSISLSLINEGPSYASKVGVGSMKQQQQTVIIDTGSSDF 
CPAP#2 LDVNATSELSXRSSPSSPLYFEGPSYGIRVSVGSNXQEQQWLDTGSSDF 
Fig 4 Sequences of two Cundzdu purupsdosis aspartic proteinases [l]. The amino acids underhned correspond to the sequences determined by 
N-terminal sequencmg of the isolated enzymes CPAP#l and CPAP#2. Key: CPAP#l, the deduced amino acid sequence for the first 100 restdues 
of Cundldu purupsdosis, the major isolated form of the aspartic proteinase: CPAP#2; the partial amino acid sequence of Cundida parapszlosrs, the 
minor isolated form of the asparttc proteinase. The amino acid sequence is gtven in the single restdue code. Characters defined in bold type are 
those restdues that are absolutely conserved between the two enzymes. Two Lys-Arg pepttdase processmg sttes are marked wtth an asterisk. The 
charactertstic catalytic motif of the aspartic proteinase family of enzymes, DTG, is indicated by up arrows (D, catalytic aspartic actd; and residues 
of the firemen’s grip, TG). The experimentally defined amino termmal sequences of the two secreted enzymes are underlined. 
and two experiments were used to identify the secreted 
products of these two genes. Primarily only one of the 
gene products (CPAP#l) was identified by sequencing 
of isolated protein from yeast culture supernatant. Sec- 
ondly a mutant of Carzdida tropicalis, whose ability to 
express an active proteinase had been disrupted was 
transformed with either of theparapsilosis genes. Resto- 
ration of proteolytic activity were only observed in the 
transfection with the CPAP#l gene. The conclusions 
from these experiments strongly suggested that the 
CPAP#2 was either a pseudogene or its product was 
expressed under as yet unidentified physiologic condi- 
tions. 
Our experimental data shows that the product of the 
CPAP#2 gene. the CPAP#2 aspartic proteinase is ex- 
pressed and secreted. The behavior of the CPAP#2 pro- 
teinase during the gel filtration purification step will be 
similar as the CPAP#l proteinase. This protein also 
constitutes only about 20% of the total enzyme recov- 
ered from the culture supernatant. These facts com- 
bined with a specific amino terminal sequence formed 
by Ser-Ser-Pro-Ser-Ser-Pro that gives a very low signal 
during amino terminal sequencing are probably respon- 
sible for the original observations that the product of 
Table I 
Comparison of the proteolyttc activity of two asparttc proteinase from 
Candida parapsilosis 
Enzyme Hemoglobm 
(U.103) 
Synthetic substrate 
k cat Kl kcJKm 
W’) (.uM) 6’ PM) 
CPAP# 1 145 36.0 101 0.3500 
CPAP#2 108 0.26 180 0.0014 
the CPAP#2 gene went undetected. Why the comple- 
mentation of the proteinase deletion mutant of Candida 
tropicalis by the Candida parapsilosis gene coding for 
CPAP#2 proteinase did not restore the proteolytic ac- 
tivity is difficult to answer. One possibility is that the 
CPAP#2 needs another aspartic proteinase or specific 
activation protease for its processing and since in the 
aspartic proteinase deficient mutant there was neither 
the original or the complementary protease, the 
CPAP#2 product was retained as the inactivated proen- 
zyme. 
Our data finally suggests that within this family of 
secreted Candida aspartic proteinases. each proteinase 
may show a variation in substrate specificity. This fea- 
ture is not new to this family of aspartic proteinases. 
Several homologous structures show that all the mem- 
bers of this proteinase family have an extended active 
site cleft which can accommodate at least seven amino 
acids of substrate in the S,-SY specificity subsites [15]. 
The spatial arrangement of the amino acids that make 
up the binding cleft and subsites are responsible for the 
discriminatory substrate specificity of each enzyme. 
Very subtle changes in the enzymes amino acid sequence 
can lead to large differences in the substrates recognized 
by these enzymes. 
It will be essential to map this specificity through 
substrate cleavage mapping for each of the Candida 
aspartic proteinases. This specificity typification is on- 
going in our laboratory. 
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